

## BFC Global Healthcare Investment Conference

BFC医疗健康国际商务合作投资研讨会

January 6, 2019

The St. Regis San Francisco

旧金山瑞吉酒店

You are invited to attend the BFC 2019 Global Healthcare Business Development and Investment Conference ([sf.bfcconference.com](http://sf.bfcconference.com)) taking place on **January 6<sup>th</sup>, 2019 at [The St. Regis San Francisco](http://The St. Regis San Francisco)**. The conference will feature key topics in the following areas:

- Biotech capital market trends in both US and China
- Licensing, the emerging trend among Chinese biotech companies
- Key successful factors for Hong Kong and Nasdaq listing
- Leading biotech company roadshows

Senior executives from more than 500 public & private healthcare companies across the biopharmaceuticals, IVD, medical device, and healthcare services sectors attended our event in 2018. More than 300 PE and VC investors from over 100 firms also attended the 2018 conference. We expect to have even greater attendance in 2019. The conference will provide an optimal environment for networking with senior executives of your potential partners. Company management teams and investors will also have the opportunity to participate in one-on-one and small group meetings through BFC Group.

More detailed information about conference registration will be sent to you in the next few days. For questions, please email: [conference@bfcgroup.biz](mailto:conference@bfcgroup.biz)

With kindest regards,  
Organizing Committee, BFC Healthcare Business Development and Investment Conference



[www.bfcgroup.biz](http://www.bfcgroup.biz)

上海九江路 675-685 号 长江新能源大厦 8 楼 E 座, 200001  
No. 675-685Jiujiang Road, Suite805, Shanghai 200001 China

[www.asymchem.com](http://www.asymchem.com)

天津经济技术开发区第七大街 71 号, 300457  
No.71,7th St.TEDA, Tianjin 300457 China

## BFC Global Healthcare Investment Conference Agenda

### Sunday, January 6, 2019

**8:00 – 9:00 Registration**

**9:00 – 9:15 Opening Remarks**

- Speaker: David Chen, Managing Director, BFC Group

### Session 1: Asymchem Global Pharma & Biotech Symposium

**9:15 – 10:15 Cross-border licensing deal trend – Perspective from leading biopharma players**

- Moderator: Christina Zhang, Partner-in-Charge of Shanghai Office, Cooley LLP
- Panelists:
  - Glenn P. Sblendorio, M.B.A., President and Chief Executive Officer, Ophthotech Corporation
  - Lila Hope, Partner in Global Life Sciences Partnering and Licensing Group, Cooley LLP
  - Samuel Murphy, VP and Head of International Business Development, Salubris Pharmaceuticals
  - Gayatri Varma, Director, Partnering & Strategy at MedImmune The Early Stage Biologics R&D Unit, AstraZeneca
  - Astrid Maria Dahl, Ph.D., MBA, Executive Business Development Director - Oncology, AstraZeneca

**10:15 – 11:15 IPO market in US and Hong Kong – Getting the best of both markets**

- Moderator: Charlie Kim, Partner and Co-Chair of Global Capital Markets Group, Cooley LLP
- Panelists:
  - David Ke, Executive Director at J.P. Morgan Investment Bank, Equity Capital Markets, J.P. Morgan Chase & Co
  - Lili Zheng, Partner in International Tax, Asia Pacific Cross-Border Services Leader, Deloitte
  - David Lau, Managing Director and Head of Investment Banking, J.P. Morgan Hong Kong
  - Y. Katherine Xu, Partner and Co-Head of the Biopharmaceutical Equity Research Group, William Blair
  - Jonie Kondracki, Partner in Global Capital Markets Group, Cooley LLP

[www.bfcgroup.biz](http://www.bfcgroup.biz)

上海九江路 675-685 号 长江新能源大厦 8 楼 E 座, 200001

No. 675-685 Jiujiang Road, Suite 805, Shanghai 200001 China

[www.asymchem.com](http://www.asymchem.com)

天津经济技术开发区第七大街 71 号, 300457

No.71,7th St.TEDA, Tianjin 300457 China

### 11:15 – 11:45 Tea Break

### 11:45 – 12:45 Access to China: Market, Regulation, Science, Investment and Solutions

- Moderator: James Gage, Chief Scientific Officer of Asymchem
- Panelists:
  - Ruyi He, Former Chief Scientist, China Food and Drug Administration (CFDA)
  - Kevin(Penghui) Chen, Founding Partner, Biotrack Capital
  - Michael Kaufman, SVP, Mersana Therapeutics
  - Jessica Li, Head of Asia Pacific Healthcare Investment Banking, Bank of America Merrill Lynch (BAML)
  - Karen Liu, Founding Partner, 3E Bioventures Capital

### 12:45 – 14:00 Asymchem Lunch Reception

## Session 2: BFC Global Healthcare BD & Investment Forum

### 14:00 – 15:00 State of Healthcare Investment in China and US

- Moderator: Yumin (Benjamin) Qiu, Partner, Advantech
- Panelists:
  - Michael Xue, Managing Director, Morningside Ventures
  - Armen B Shanafelt, General Partner, Lilly Ventures
  - Xiaobo Lu, Partner, Sequoia Capital China
  - Yining Zhao, Co-Founder & Executive Chairman, Transcenta Holding

### 15:00 – 15:30 Tea Break

### 15:30 – 18:00 Company Road Show

[www.bfcgroup.biz](http://www.bfcgroup.biz)

上海九江路 675-685 号 长江新能源大厦 8 楼 E 座, 200001

No. 675-685Jiujiang Road, Suite805, Shanghai 200001 China

[www.asymchem.com](http://www.asymchem.com)

天津经济技术开发区第七大街 71 号, 300457

No.71,7th St.TEDA, Tianjin 300457 China

## Conference Venue

**The St. Regis San Francisco—125 3rd Street San Francisco, California 94103, United States**  
**Phone: +1 (415) 284-4000.**

As the ultra luxury brand of Marriott, St. Regis is renowned for its tradition of innovation and impeccable service at the best addresses in the world since its founding in 1904. The St. Regis San Francisco is an upscale five star hotel located in the heart of one of the city's most vibrant neighborhoods, within walking distance to the Union Square, museums, restaurants, and shopping.



[www.bfcgroup.biz](http://www.bfcgroup.biz)

上海九江路 675-685 号 长江新能源大厦 8 楼 E 座, 200001  
No. 675-685 Jiujiang Road, Suite 805, Shanghai 200001 China

[www.asymchem.com](http://www.asymchem.com)

天津经济技术开发区第七大街 71 号, 300457  
No. 71, 7th St. TEDA, Tianjin 300457 China

## Speaker Profile



### **David Chen, Managing Director, BFC Group**

Mr. Chen has over 20 years of management experience in pharmaceutical, diagnostic and medical devices companies in both the US and China. He was a scientist with Bayer Corporation. He was also a business member of a major product launch team with Eli Lilly in the US. He then served as acting CFO at Shanghai Sunway Biotech, a specialty pharmaceutical company focused on oncology, where he was in charge of overall business development and finance. As a co-founder of BFC Group, he has been involved in many cross-border engagements covering business development, private placement, and mergers and acquisitions. His clients include public and private companies, as well as private equity and venture capital funds in the US, Europe and China. Mr. Chen is a published author and inventor. He is also a frequent speaker at healthcare investment conferences. Mr. Chen received his MBA from Kellogg School of Management of the Northwestern University.



### **Christina Zhang, Partner-in-Charge of Shanghai Office, Cooley LLP**

Christina Zhang is a partner and the chief representative of Cooley's Shanghai office. Christina has more than 20 years of practice experience, gained through private practice and in-house experience in the U.S. and China, including more than ten years in the life sciences industry as in-house Counsel for Merck in the U.S. and Wyeth in China. Christina represents clients in cross border transactions, especially in life science and high tech industries and other industrial sectors. Christina has represented U.S. clients in their investments into China, advising on licensing and partnership transactions, entry strategies, setting up joint ventures, acquisitions and divestitures, distribution and marketing and other issues. Christina has also represented Chinese investment funds and companies in making investments and acquisitions and doing business overseas.

[www.bfcgroup.biz](http://www.bfcgroup.biz)

上海九江路 675-685 号 长江新能源大厦 8 楼 E 座, 200001

No. 675-685 Jiujiang Road, Suite 805, Shanghai 200001 China

[www.asymchem.com](http://www.asymchem.com)

天津经济技术开发区第七大街 71 号, 300457

No.71,7th St.TEDA, Tianjin 300457 China



**Michael Xue, Managing Director, Morningside Ventures**

Mr. Xue joined Morningside Ventures in 2005, in charge of healthcare related investment activities of Great China region. Michael has engaged in and led many investments in biotech, medtech and healthcare start-ups. He sits on boards of companies including ARK, Zensun, Medtrum, Luqa and Omni Pharmaceutical. Michael Xue holds a MBA degree from Cheung Kong Graduate School of Business, and a M.Sc. degree in organic chemistry from Nankai University.



**Kevin (Penghui) Chen, Founding Partner, Biotrack Capital**

Kevin (Penghui) Chen is founding partner at Biotrack Capital. Previously, he was a partner at Sequoia Capital China, responsible for healthcare investment. Before Sequoia, Mr. Chen set up the first healthcare fund at Everbright Holdings and served as head of Everbright Healthcare Fund. Mr. Chen has led investments in over 20 leading healthcare companies in China such as BGI, Betta Pharma, Yuwell Medical, Zai Lab, and Amcare Hospital etc. Before Everbright, he was the President, COO & CFO of ShangPharma Corporation between 2008 and 2011 and took the company public at NYSE in 2010. Mr. Chen also worked as research scientist at Ligand Pharmaceuticals in San Diego, California. Mr. Chen holds a bachelor degree in chemistry from Nanjing University, master degree in medicinal chemistry from Tulane University and an MBA from Kellogg School of Management, Northwestern University.

[www.bfcgroup.biz](http://www.bfcgroup.biz)

上海九江路 675-685 号 长江新能源大厦 8 楼 E 座, 200001

No. 675-685 Jiujiang Road, Suite 805, Shanghai 200001 China

[www.asymchem.com](http://www.asymchem.com)

天津经济技术开发区第七大街 71 号, 300457

No.71,7th St.TEDA, Tianjin 300457 China



**Yumin (Benjamin) Qiu, CFA, CMA, Partner, Advantech**

Mr. Qiu has 14 years of experience in healthcare investment, consulting and hospital management. Since joining Advantech in 2013, Benjamin has led deals covering a wide spectrum across healthcare space including pharmaceutical/biological innovative drugs (Zai Lab, HarbourBioMed, Synermore, KBP), medical services (Arrail Dental), medical devices (HealForce), precision medicine (Genetron Health), mobile health (WiwidYoukang), AlphaMab and TOT Pharma. Before joining Advantech, Ben led deals of Kangning Hospitals Group (HKSE:2120) and Arrail Dental, as a key member of a healthcare dedicated private equity fund – GL Capital. As one of the founding members of Healthcare Advisory team at PwC China, Ben built up a client base including big pharma companies and investment firms, providing strategy, operation improvement consulting and deal due diligence services. Ben started his healthcare career by working with Vancouver General Hospital as an analyst/project leader. Ben graduated from University of British Columbia with an MBA in Finance, and Eastern China University of Technology with a Bachelor Degree in Power Engineering. Ben also holds CFA (Chartered Financial Analyst) and CMA (Certified Management Accountant) designations.



**Charlie Kim, Partner and Co-Chair of Global Capital Markets Group, Cooley LLP**

Charlie Kim is co-chair of Cooley's global capital markets practice group. For years, Charlie has been an international IPO leader and the most active IPO attorney in California. He has worked on over 50 successfully completed public company securities transactions in the last 2 years alone. Charlie specializes in representing U.S. and non-U.S. issuers, investment banking firms and venture capital firms in a wide range of securities offerings, with particular expertise in the healthcare sector.

Charlie has been named a Top 100 Lawyer in California across all specialties by the Daily Journal, ranked as a leader in Capital Markets: Debt & Equity by Chambers USA, named a Southern California as well as San Diego Super Lawyer by Thomson Reuters, and recognized as a San Diego Top Attorney by The Daily Transcript in multiple years.

[www.bfcgroup.biz](http://www.bfcgroup.biz)

上海九江路 675-685 号 长江新能源大厦 8 楼 E 座, 200001

No. 675-685Jiujiang Road, Suite805, Shanghai 200001 China

[www.asymchem.com](http://www.asymchem.com)

天津经济技术开发区第七大街 71 号, 300457

No.71,7th St.TEDA, Tianjin 300457 China



**Lila Hope, Partner in Global Life Sciences Partnering and Licensing Group, Cooley LLP**

Lila Hope is a partner in Cooley's global life sciences partnering and licensing group. She focuses on the representation of life sciences companies discovering, developing and marketing pharmaceutical, vaccine, medical device, diagnostic and digital health products. She counsels clients ranging from privately-held companies to Fortune 500 companies. Lila specializes in transactions involving complex intellectual property, business, operational and legal issues, including strategic partnerships, discovery and option deals, and cross-border licenses. In addition, she counsels clients' management, operational and legal teams on matters involving licensing, supply, distribution, clinical trials, research collaborations and vendor services. She is also regularly involved in the evaluation of a company's product rights and operational risks in connection with financing, public offering and M&A transactions.

Some representative transactions Lila closed in 2018 include two immunotherapy platform collaborations (FATE/ONO and Xyphos/PICI), five cross-border transactions (I-Mab/Morphosys, Rigel/Kissei, Zai/TESARO, Ascendis/VISEN and Ark/Roche), and a platform collaboration between Takeda Pharmaceuticals and Denali.



**David Ke, Executive Director, J.P. Morgan Investment Bank, Healthcare Equity Capital Markets**

David has been with J.P. Morgan for 11 years and has worked on over 150 healthcare equity offerings in a bookrunner capacity. David joined J.P. Morgan in 2007 and has worked within the Equity Capital Markets since 2011.

Prior to that, he was in the Financial Institutions Credit Risk Management group. David graduated from the NYU Stern School of Business and received a degree in Finance and International Business.

[www.bfcgroup.biz](http://www.bfcgroup.biz)

上海九江路 675-685 号 长江新能源大厦 8 楼 E 座, 200001

No. 675-685 Jiujiang Road, Suite 805, Shanghai 200001 China

[www.asymchem.com](http://www.asymchem.com)

天津经济技术开发区第七大街 71 号, 300457

No.71,7th St.TEDA, Tianjin 300457 China





**David P.W. Lau, Head of Hong Kong Investment Banking, J.P. Morgan**

David is Head of Global Investment Banking, Hong Kong. He joined J.P. Morgan in 1995. Prior to J.P. Morgan, David worked in Private Equity. David also worked at both the Listing Division of the Hong Kong Stock Exchange and the Hong Kong Securities and Futures Commission between 2002 and 2004, where he helped formulate capital market policies.

David has worked on a large number of Capital Markets and M&A transactions and has served various functions during his career at J.P. Morgan, including Equity Capital Market and China Corporate Finance. David is also a member of the Listing Committee of HKEx since July 2017.

David graduated from the University of California at Los Angeles majoring in Business Economics. He is fluent in English, Mandarin and Cantonese.



**Ruyi He, Former Chief Scientist, Center for Drug Evaluation (CDE), China Food and Drug Administration (CFDA)**

Dr. Ruyi He is the former Chief Scientist in the Center for Drug Evaluation (CDE), China Food and Drug Administration (CFDA).

Dr. He has rich drug regulatory experience in both China and the USA. He had worked in the US FDA for 17 years, before he joined CDE/CFDA. Dr. He received many awards for his excellent work in the US FDA. Dr. He is a board certified physician for internal medicine and licensed in the State of Virginia and West Virginia.

[www.bfcgroup.biz](http://www.bfcgroup.biz)

上海九江路 675-685 号 长江新能源大厦 8 楼 E 座, 200001

No. 675-685 Jiujiang Road, Suite 805, Shanghai 200001 China

[www.asymchem.com](http://www.asymchem.com)

天津经济技术开发区第七大街 71 号, 300457

No.71,7th St.TEDA, Tianjin 300457 China



**Dr. James Gage, Chief Scientific Officer, Asymchem**

Dr. Gage is Chief Scientific Officer of Asymchem. He earned his Ph.D. in Chemistry with Professor David Evans at Harvard University. Dr. Gage has 26 years of experience in process chemistry and other aspects of pharmaceutical CMC. Prior to joining Asymchem in early 2006, Dr. Gage worked in process chemistry and pharmaceutical development in the US pharma industry for 14 years. He manages implementation of commercial processes at Asymchem and seeks ways to expand the company's capabilities through development and application of new technology.



**Samuel Murphy, VP and Head of International Business Development, Salubris Pharmaceutical**

Sam currently serves as VP and Head of International Business Development for Salubris Pharmaceuticals and its US subsidiary Salubris Biotherapeutics. His responsibilities include sourcing, evaluation, and negotiation of licensing, strategic investment and acquisition opportunities originating outside of China. Prior to joining Salubris, Sam worked for ten years in strategy consulting and transaction advisory services across several global firms including Simon-Kucher & Partners and IMS (now IQVIA), where he was a Senior Principal in the strategy consulting division and Managing Director of IMS Health Capital. Sam's commercial strategy engagements encompassed 18 of the top 25 pharmaceutical companies, and his transaction advisory work included financings, alliances and acquisitions collectively exceeding \$2B USD. Sam completed his B.A. in Biochemistry, Ph.D. in Molecular Biology and Post-Doctoral Fellowship in Gene Therapy and Translational Medicine at the University of Pennsylvania, where he focused principally on gene therapy during his 13 years of bench research. Sam currently serves on the boards of GO Therapeutics and MedAlliance, and as a board observer at Mercator Medsystems.

[www.bfcgroup.biz](http://www.bfcgroup.biz)

上海九江路 675-685 号 长江新能源大厦 8 楼 E 座, 200001

No. 675-685 Jiujiang Road, Suite 805, Shanghai 200001 China

[www.asymchem.com](http://www.asymchem.com)

天津经济技术开发区第七大街 71 号, 300457

No. 71, 7th St. TEDA, Tianjin 300457 China



**Y. Katherine Xu, Partner and Co-Head of the Biopharmaceutical Equity Research Group, William Blair**

Katherine Xu is currently the Partner and Co-Head of the Biopharmaceutical Equity Research Group at William Blair, based in New York. Prior to William Blair, Katherine was senior vice president and senior biotechnology analyst at Wedbush Securities, vice president and senior biotechnology analyst at Credit Suisse, and a senior biotechnology analyst at Pacific Growth Equities. Katherine was recognized by the Financial Times/StarMine World's Top Analysts listing, ranking No. 7 overall for stock-picking in the United States in 2010, and No. 2 for stock-picking in biotechnology in 2011; she received the No. 2 ranking in The Wall Street Journal's Best on the Street listing in 2011 as well. Before her move to equity research, Katherine worked in investment banking for two years. Katherine holds a Ph.D. in developmental biology and a Ph.D. minor in engineering-economic systems and operations research from Stanford University Schools of Medicine and Engineering, respectively. She attended Peking University in Beijing and Kalamazoo College in Michigan, where she gained her B.A. with honors.



**Armen Shanafelt, General Partner, Lilly Ventures**

Armen Shanafelt is a General Partner at Lilly Ventures. Prior to joining Lilly Ventures in 2009, he had over 24 years of operational experience in the pharmaceutical, biotechnology, and diagnostic businesses. Dr. Shanafelt serves as a director on the boards of Aeglea Biotherapeutics (AGLE), Aileron Therapeutics (ALRN), Protagonist Therapeutics (PTGX), Surface Oncology (SURF), and Symic Bio. He is a Kauffman Fellow (Class 14).

He received his B.S. Degree in Chemistry and Physics from Pacific Lutheran University and his Ph.D. in Chemistry from the University of California, Berkeley, and completed his postdoctoral work at DNAX Research Institute.

[www.bfcgroup.biz](http://www.bfcgroup.biz)

上海九江路 675-685 号 长江新能源大厦 8 楼 E 座, 200001

No. 675-685 Jiujiang Road, Suite 805, Shanghai 200001 China

[www.asymchem.com](http://www.asymchem.com)

天津经济技术开发区第七大街 71 号, 300457

No.71,7th St.TEDA, Tianjin 300457 China



**Glenn P. Sblendorio, M.B.A., President and Chief Executive Officer, Ophthotech Corporation**

Glenn Sblendorio, M.B.A., is Chief Executive Officer and President of Ophthotech Corporation. He joined Ophthotech in 2016 as Executive Vice President, Chief Operating Officer and Chief Financial Officer and was appointed President in January 2017 while continuing to serve as Chief Financial Officer. He ceased being CFO in April 2017. Mr. Sblendorio served as a member of the Board of Directors of Ophthotech from 2013 to 2016 and rejoined the Board in May 2017. Prior to joining Ophthotech, he served as President and Chief Financial Officer and member of the Board of Directors of The Medicines Company from 2006 to 2016. Mr. Sblendorio served as Executive Vice President and Chief Financial Officer of Eyetech Pharmaceuticals, Inc. from 2002 through 2005 when it was sold to OSI Pharmaceuticals. From 2000 through 2002, he held the title of Senior Vice President of Business Development for The Medicines Company. His pharmaceutical experience also includes 12 years at Hoffmann-LaRoche, Inc. in a variety of senior financial positions. Mr. Sblendorio currently serves on the Board of Directors of Amicus Therapeutics and Intercept Pharmaceuticals. Mr. Sblendorio received his BA from Pace University and an MBA from Fairleigh Dickinson University and is a graduate of the Harvard Business School Advanced Management Program.



**Jonie Kondracki, Partner in Global Capital Markets Group, Cooley LLP**

Jonie Ing Kondracki is a partner in Cooley's global capital markets practice group. Jonie is amongst the most active IPO attorneys in California. She specializes in representing U.S. and non-U.S. issuers, investment banking firms and venture capital firms in a wide range of securities offerings. She also represents companies with respect to general corporate and securities matters, including corporate governance issues, Exchange Act reporting obligations and stock exchange requirements. Her experience also includes representation of companies in mergers and acquisitions transactions and restructurings.

[www.bfcgroup.biz](http://www.bfcgroup.biz)

上海九江路 675-685 号 长江新能源大厦 8 楼 E 座, 200001

No. 675-685Jiujiang Road, Suite805, Shanghai 200001 China

[www.asymchem.com](http://www.asymchem.com)

天津经济技术开发区第七大街 71 号, 300457

No.71,7th St.TEDA, Tianjin 300457 China



**Lili Zheng, Partner in International Tax, Asia Pacific Cross-Border Services Leader, Deloitte**

Lili is a senior US international tax partner with substantial experience in cross-border tax planning. Leveraging her extensive on-the-ground work experience in Deloitte offices in San Francisco, Tokyo, Beijing, San Jose and Hong Kong, she provides practical and implementable solutions to clients. Lili has extensive knowledge in advising clients in various industries including VC/PE funds, Life Sciences & Healthcare, and TMT on their cross-border investment structure, M&A, IPO positioning, entry and exit strategies. She has a deep understanding of the unique considerations of MNCs as well as investors from US, China and other Asian countries. Lili is a frequent speaker at various conferences and was voted by International Tax Review as one of the top US tax advisors for multiple years. Euromoney named her as one of the Leading Women in Business Law and has listed her as one of the World's Leading Tax Advisers annually since 2012. Lili is fluent in Mandarin and Cantonese. She is a licensed CPA in California and New York and a member of AICPA.



**Gayatri Varma, Director, Partnering & Strategy at MedImmune the early stage biologics R&D unit, AstraZeneca**

Gayatri Varma, Ph.D. is Director, Partnering & Strategy at MedImmune the early stage biologics R&D unit of AstraZeneca. At MedImmune, Gayatri leads all business development activities for the Respiratory, Inflammation & Autoimmunity therapeutic area. In her role she engages with academia, government and companies to set up collaborations and partnerships as well as in and out licensing of assets. Gayatri came to MedImmune from the University of Maryland where she was Executive Director of the Office of Technology Commercialization. She joined the OTC team in 1997 as a graduate student and advanced through the ranks to her appointment as Executive Director. She holds a B.Sc in microbiology from Bombay University, a M.Sc in microbiology from MS University in Baroda, India and a Ph.D.in molecular and cell biology from the University of Maryland. She is a registered Patent Agent with the USPTO. She is a Director on the Board of AUTM in the US and is also a member of the Life Sciences Sector Leadership Committee for Licensing Executives Society.

[www.bfcgroup.biz](http://www.bfcgroup.biz)

上海九江路 675-685 号 长江新能源大厦 8 楼 E 座, 200001

No. 675-685Jiujiang Road, Suite805, Shanghai 200001 China

[www.asymchem.com](http://www.asymchem.com)

天津经济技术开发区第七大街 71 号, 300457

No.71,7th St.TEDA, Tianjin 300457 China



**Astrid Maria Dahl, Ph.D., MBA, Executive Business Development Director - Oncology, AstraZeneca**

Astrid Maria Dahl is Executive Business Development Director, Scientific Partnering & Alliances – Oncology at AstraZeneca, a global pharmaceutical company operating in more than 100 countries worldwide. In this role she is responsible for global licensing and partnering with regards to oncology assets in early clinical development and research. Maria has a dual technical and business background and more than fifteen years of experience in the US and UK biotechnology and pharmaceutical industry, primarily in the areas of business development and portfolio management. Following a Ph.D. in Tumor Immunology from the Imperial Cancer Research Fund/University College London in the UK, she did her post-doctoral work in immunology at Harvard Medical School in Boston, USA. She then obtained an MBA from the University of California at Berkeley and moved into industry. She initially worked in the business development team at the San Francisco based biotechnology company Cell Genesys prior to moving to London to work for IPSEN from 2004 to 2012. At IPSEN she was responsible for oncology in the corporate business development team prior to being promoted in 2008 to Vice-President to head the entire oncology portfolio management team. She joined AstraZeneca's business development team in early 2012 and is based in the offices in Cambridge, UK. She also serves on the board of Apollo Therapeutics (UK) and the Swedish Chamber of Commerce (UK).



**Xiaobo Lu, Partner, Sequoia Capital China**

Mr. Lu is the healthcare Partner of Sequoia Capital China focusing on healthcare investment. During the past 8 years, he led over 30 healthcare investments, including: BGI (300676), Betta Pharmaceuticals (300558), Konruns Pharmaceuticals (603590), Innovent (01801 HK), Chipscreen, Geneseeq, Jingfeng Pharmaceuticals (000908), Zhongankang (000150), etc. Before that, Mr. Lu had over 15 years of experience in pharmaceuticals sales and marketing. He worked in China Resource Sanjiu for almost ten years with rich experience and knowledge in Chinese pharmaceutical market and identifying healthcare investment opportunities. Mr. Lu obtained a bachelor's degree in biochemistry engineering from Zhejiang University, an MBA degree from Tsinghua University and a finance EMBA degree from Tsinghua PBCSF (in reading).

[www.bfcgroup.biz](http://www.bfcgroup.biz)

上海九江路 675-685 号 长江新能源大厦 8 楼 E 座, 200001

No. 675-685 Jiujiang Road, Suite 805, Shanghai 200001 China

[www.asymchem.com](http://www.asymchem.com)

天津经济技术开发区第七大街 71 号, 300457

No.71,7th St.TEDA, Tianjin 300457 China



**Jessica Li, head of Asia Pacific healthcare investment banking, Bank of America Merrill Lynch (BAML)**

Dr. Li is Head of Asia Pacific healthcare investment banking at Bank of America Merrill Lynch (BAML). Prior to that, Dr. Li was head of Greater China healthcare research with BAML, Jefferies and China International Capital Corporation (CICC) for a total of 8 years. Prior to CICC, Dr. Li was a US biotech analyst at Goldman Sachs in New York City.

Dr. Li obtained her Ph.D. in molecular biology from the University of Utah, MBA from the University of Chicago, and Bachelor Degree in Genetic Engineering from Fudan University.



**Yining Zhao, Co-Founder & Executive Chairman, Transcenta Holding**

Dr. Yining Zhao is the Co-founder and Executive Chairman of Transcenta Holding, a world-class biotherapeutics company with fully-integrated capabilities in research, development, regulatory and manufacturing of biologics. Transcenta Holding consists of two companies, namely HJB and MabSpace.

Prior to his entrepreneurial career, Dr. Zhao has been working in the areas of Strategy Management, Business Development, Product Development and M&A at multinational biopharmaceutical companies for around 20 years. He was Executive Strategy Director of Global Commercial Operations at Amgen based in Thousand Oaks, California where he was leading the market entry strategy, business development and commercialization of biosimilars in 30 countries outside US and EU. Prior to Amgen, Dr. Zhao was the Asia Strategy Lead at Pfizer based in New York, overseeing the Asia strategy across small molecule, biologics and vaccine.

Currently, Dr. Zhao is the Chairman of Veritas Genetics Inc. and CEO of Intuition Biosciences Inc., which are also co-founded by him and respectively specializes in human genetic testing and microbiome therapy. Dr. Zhao received his B.S. in Pharmaceutical Sciences from Fudan University (Shanghai, China), Ph.D. in Analytical Chemistry from Ghent University (Ghent, Belgium), and MBA from Massachusetts Institute of Technology (Cambridge, USA). Yining has contributed more than 30 peer-reviewed publications and book chapters.

[www.bfcgroup.biz](http://www.bfcgroup.biz)

上海九江路 675-685 号 长江新能源大厦 8 楼 E 座, 200001

No. 675-685Jiujiang Road, Suite805, Shanghai 200001 China

[www.asymchem.com](http://www.asymchem.com)

天津经济技术开发区第七大街 71 号, 300457

No.71,7th St.TEDA, Tianjin 300457 China



**Michael Kaufman, Senior Vice President of Chemistry, Manufacturing and Controls, Mersana Therapeutics**

Dr. Kaufman joined Mersana in February 2016, bringing more than two decades of experience in process development, scale-up, formulation and supply chain management across multiple therapeutic modalities, including immunoconjugates. Prior to Mersana, Dr. Kaufman served as Biogen's Vice President, Technical Development, where he provided technical leadership for all products from preclinical to commercial stage. Dr. Kaufman also spent 10 years at Millennium Pharmaceuticals, most recently as Vice President, Pharmaceutical Sciences, leading all aspects of chemistry, manufacturing and controls. Dr. Kaufman began his pharmaceutical career at Merck and Co., Inc., spending 15 years in various roles of increasing responsibility. Dr. Kaufman holds a Ph.D. in Physical Organic Chemistry from the University of California, Berkeley, and a B.S. in Chemistry from State University of New York, Stony Brook. He was a post-doctoral fellow at Louisiana State University and an instructor at the University of California



**Karen Liu, Founding Partner, 3E Bioventures Capital**

Dr. Karen Liu is a founding partner of 3E Bioventures Capital, a fund that focuses on venture investments in healthcare related sectors, such as drug, device, diagnostics, increasingly, interdisciplinary innovations at the frontier of BT (Biotech) and IT (information technology). While 3E primarily invests in China, it is also actively exploring cross-border investment opportunities with China angle or can leverage China advantages.

Dr. Karen Liu has been active in China healthcare venture investment since 2006. Her past investments include device companies such as Reach Surgical, Sinomed, diagnostic companies such as Biochain, Micropoint, BGI, drug related companies such as Chiral Quest, Shenogen and mobile health company such as Apricot Forest. Prior to 3E Bioventures, Karen was a partner at Kaiwu Capital in charge of healthcare investment from 2011-2015 and before that, was Managing Director at CRCI Capital from 2007-2011, also in charge of healthcare investment.

In 2006, Karen co-founded Shenogen Pharma, a company developing innovative liver cancer therapeutics, and was its first angle investor. From 2000-2004, she was an entrepreneur and senior team member of 3721, an Internet search company founded by Internet veteran Hongyi Zhou. She helped build up the small internet company and achieved profitability and eventually sold it to Yahoo in early 2004. Karen Liu also worked as a consultant at McKinsey & Company from 1998-2000.

[www.bfcgroup.biz](http://www.bfcgroup.biz)

上海九江路 675-685 号 长江新能源大厦 8 楼 E 座, 200001

No. 675-685 Jiujiang Road, Suite 805, Shanghai 200001 China

[www.asymchem.com](http://www.asymchem.com)

天津经济技术开发区第七大街 71 号, 300457

No.71,7th St.TEDA, Tianjin 300457 China



<b>Time Slot</b>	<b>Room#1</b>	<b>Room#2</b>
<b>15:30-15:40</b>	<b>Dyadic</b>	<b>TCL Medical Imaging Technology</b>
<b>15:40-15:50</b>		<b>Aucta Healthcare</b>
<b>15:50-16:00</b>	<b>CloudBreak</b>	<b>Asymchem</b>
<b>16:00-16:10</b>	<b>Ophthotech Corporation</b>	<b>TenNor Therapeutics</b>
<b>16:10-16:20</b>	<b>Virogen</b>	<b>Adamerck</b>
<b>16:20-16:30</b>	<b>Achillion Pharmaceuticals</b>	<b>Phagelux</b>
<b>16:30-16:40</b>	<b>Sinnowa</b>	<b>Transcenta</b>
<b>16:40-16:50</b>	<b>Hycor</b>	<b>Phanes</b>
<b>16:50-17:00</b>	<b>MatriVax</b>	<b>Bostal</b>
<b>17:00-17:10</b>	<b>Vigeo</b>	<b>Impact Therapeutics Inc</b>
<b>17:10-17:20</b>	<b>HawkEye Bio</b>	<b>CARsgen</b>

[www.bfcgroup.biz](http://www.bfcgroup.biz)

上海九江路 675-685 号 长江新能源大厦 8 楼 E 座, 200001  
 No. 675-685Jiujiang Road, Suite805, Shanghai 200001 China

[www.asymchem.com](http://www.asymchem.com)

天津经济技术开发区第七大街 71 号, 300457  
 No.71,7th St.TEDA, Tianjin 300457 China

## Sponsor Introduction

- **Co-Host Sponsor**



- **Platinum Sponsor**



**bioBAY**



**聚明创投**  
MING BIOVENTURES

- **Gold Sponsor**

**MORNINGSIDE**  
VENTURES

**Deloitte.**



- **Exclusive Sponsor-Law Firm**

**Cooley** 科律

[www.bfcgroup.biz](http://www.bfcgroup.biz)

上海九江路 675-685 号 长江新能源大厦 8 楼 E 座, 200001  
No. 675-685Jiujiang Road, Suite805, Shanghai 200001 China

[www.asymchem.com](http://www.asymchem.com)

天津经济技术开发区第七大街 71 号, 300457  
No.71,7th St.TEDA, Tianjin 300457 China